Financial reports
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K/A
2022 FY
Annual report (amended)
20 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Current reports
8-K
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
29 Feb 24
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
1 Nov 23
8-K
Innoviva Appoints Stephen Basso as Chief Financial Officer
25 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Aug 23
8-K
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
2 Aug 23
8-K
Departure of Directors or Certain Officers
11 Jul 23
8-K
Corporate Presentation May 2023
24 May 23
8-K
Submission of Matters to a Vote of Security Holders
23 May 23
8-K
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent
9 May 23
Registration and prospectus
S-8
Registration of securities for employees
13 Nov 23
SC TO-T/A
Third party tender offer statement (amended)
22 Aug 22
SC TO-T/A
Third party tender offer statement (amended)
16 Aug 22
SC TO-T
Third party tender offer statement
25 Jul 22
SC TO-C
Information about tender offer
11 Jul 22
425
Business combination disclosure
11 Jul 22
SC 13E3/A
Going private transaction (amended)
8 Jul 22
SC TO-T/A
Third party tender offer statement (amended)
8 Jul 22
SC 13E3/A
Going private transaction (amended)
17 Jun 22
SC TO-T/A
Third party tender offer statement (amended)
17 Jun 22
Proxies
DEFA14A
Additional proxy soliciting materials
17 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
25 Mar 22
DEFA14A
Additional proxy soliciting materials
5 May 21
DEF 14A
Definitive proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEFA14A
Additional proxy soliciting materials
12 Mar 20
DEF 14A
Definitive proxy
11 Mar 20
DEFA14A
Additional proxy soliciting materials
13 Mar 19
Other
CT ORDER
Confidential treatment order
6 Apr 17
CT ORDER
Confidential treatment order
6 Apr 17
UPLOAD
Letter from SEC
17 Mar 17
CORRESP
Correspondence with SEC
7 Mar 17
UPLOAD
Letter from SEC
10 Jan 17
CORRESP
Correspondence with SEC
14 Dec 16
UPLOAD
Letter from SEC
5 Dec 16
CORRESP
Correspondence with SEC
1 Nov 16
UPLOAD
Letter from SEC
25 Oct 16
CORRESP
Correspondence with SEC
22 Sep 16
Ownership
4
Stephen Basso
7 Mar 24
4
Matthew Ronsheim
7 Mar 24
4
Marianne Zhen
7 Mar 24
4
Pavel Raifeld
7 Mar 24
SC 13D/A
Armata Pharmaceuticals, Inc.
4 Mar 24
4
Matthew Ronsheim
22 Feb 24
4
Marianne Zhen
22 Feb 24
SC 13G/A
PUTNAM INVESTMENTS LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 24